Welcome to our dedicated page for Merck & news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & stock.
Merck & Co., Inc. reports news across a global pharmaceutical business known as MSD outside the United States and Canada. Company updates center on human health products for areas such as oncology, cardiometabolic disease and infections; vaccines including Gardasil; and Merck Animal Health medicines, devices and customer-support systems.
Recurring developments include FDA approvals, clinical and regulatory disclosures, research publications, pipeline additions, business development transactions, material agreements, capital-structure updates, governance matters, and operating and financial results. Recent themes include the approved HIV-1 regimen IDVYNSO, investigational programs such as enlicitide decanoate and TERN-701, technology partnerships for research, manufacturing and commercial functions, and animal health digital engagement initiatives.
Synergis Software (NYSE:ED) launched Adept Cloud, a cloud-native SaaS engineering document management platform for asset-intensive industries such as manufacturing, utilities, oil and gas, chemicals, pharmaceuticals, and mining. It delivers the full Adept capabilities in a browser-based, fully hosted and continuously updated environment.
Adept Cloud includes built-in Adept AI to surface engineering information faster and support document-intensive work. Plans—Essentials, Professional, and Enterprise—offer unlimited users with no per-seat costs. Synergis highlights strong user feedback, with 95% of verified G2 reviews rated four or five stars.
Merck (NYSE:MRK) reported that the pivotal Phase 3 TroFuse-005 trial of investigational TROP2-directed ADC sacituzumab tirumotecan (sac-TMT) in certain patients with advanced or recurrent endometrial cancer met its primary endpoints of overall survival (OS) and progression-free survival (PFS) versus physician’s choice chemotherapy.
The study also met its key secondary endpoint of objective response rate and showed a safety profile consistent with prior sac-TMT studies, with no new safety signals. According to Merck, TroFuse-005 is the first global Phase 3 trial to show statistically significant OS and PFS benefit for a TROP2 ADC in this setting.
Merck (NYSE:MRK) will present data from more than 100 oncology abstracts across over 25 cancer types at ASCO 2026 (May 29–June 2). Key highlights include 5-year follow-up from KEYNOTE-942 for intismeran autogene plus KEYTRUDA in melanoma and final analysis of KEYNOTE-522 in early-stage TNBC.
Additional Phase 3 data feature sacituzumab tirumotecan in NSCLC, KEYTRUDA plus Trodelvy in metastatic TNBC, and long-term results across genitourinary, gastrointestinal, gynecologic and biomarker-focused studies. Merck will also host an Oncology Investor Event on June 1, 2026.
Merck (NYSE: MRK) published a Science paper (May 7, 2026) describing a large-scale biocatalytic synthesis of enlicitide decanoate, an investigational oral PCSK9 inhibitor.
The paper details enzyme-enabled peptide fragment formation, coupling, macrocyclization, and crystallization-based purifications that enable scalable, sustainable manufacture of this macrocyclic peptide.
Merck Animal Health selected Salesforce (NYSE: CRM) Agentforce Life Sciences to create a unified, 360-degree customer engagement platform across veterinarians, pet owners, and production animal farmers. The deployment uses Agentforce 360 and Data 360 to consolidate device data, prescription history, omni-channel service, personalized marketing, subscriptions, warranties, and sales workflows.
The initiative aims to reduce waste and cost to serve, improve access to medicines and devices, increase acquisition and retention, and centralize monitoring and biopharma systems onto a single platform.
Merck (NYSE: MRK) completed the acquisition of Terns Pharmaceuticals on May 5, 2026, paying $53.00 per share in cash and making Terns a wholly‑owned subsidiary.
The deal covers ~86.36% of Terns shares tendered and converts remaining shares into the same cash consideration; TERN‑701, an oral allosteric BCR::ABL1 inhibitor with FDA Breakthrough Therapy Designation for certain CML patients, joins Merck’s oncology pipeline. The transaction is expected to be treated as an asset acquisition with a $5.8 billion R&D charge and a ~$0.12 EPS negative impact in 2026.
Knoa Pharma (V) began operations on May 1, 2026 as a public health–focused pharmaceutical company wholly owned by the not‑for‑profit Knoa Foundation (a 501(c)(4)).
The company will manufacture existing medicines, including opioid analgesics, under a strict operating injunction with independent monitoring, will not promote opioid products, and will use value generated to fund opioid abatement and no‑profit access to overdose reversal and OUD treatments.
Merck (NYSE: MRK) reported Q1 2026 sales of $16.3 billion (+5% or +3% ex-FX) with KEYTRUDA sales of $8.03 billion (+12%). GAAP loss per share was $1.72 and non-GAAP loss per share was $1.28, both reflecting a $3.62 per-share charge for the Cidara acquisition. Merck narrowed and raised its 2026 sales outlook to $65.8–$67.0 billion and raised the non-GAAP EPS midpoint to $5.10. The company announced an agreement to acquire Terns, expected to close in May with an ~$5.8 billion one-time charge (~$2.35/share).
Merck (NYSE: MRK) launched the Playing with Heart educational program with nine MLB clubs, baseball legends, and WomenHeart to raise awareness of LDL-C ("bad" cholesterol) and its link to heart attack and stroke risk. The program includes in-stadium events and a national ambassador, Albert Pujols.
According to Merck, the campaign encourages adults to discuss LDL-C with their doctors and directs audiences to playingwithheart.com for resources; the release notes about 800,000 U.S. heart attacks occur annually.
Merck (NYSE: MRK) announced the Hart-Scott-Rodino Act waiting period in connection with its pending acquisition of Terns Pharmaceuticals (Nasdaq: TERN) expired at 11:59 p.m. ET on April 23, 2026. Merck previously commenced a cash tender offer to buy all outstanding Terns shares for $53.00 net per share.
The expiration of the HSR waiting period satisfies one required condition for consummating the tender offer; closing remains subject to additional conditions in the Schedule TO, including receipt of tenders representing more than 50% of Terns outstanding shares.